[1]曹金强,毛士明,汪万国.奥扎格雷联合依达拉奉治疗急性脑梗死的效果[J].医学信息,2020,33(01):140-141.[doi:10.3969/j.issn.1006-1959.2020.01.044]
　CAO Jin-qiang,MAO Shi-ming,WANG Wan-guo.Effect of Ozagrel Combined with Edaravone on Acute Cerebral Infarction[J].Medical Information,2020,33(01):140-141.[doi:10.3969/j.issn.1006-1959.2020.01.044]
点击复制

奥扎格雷联合依达拉奉治疗急性脑梗死的效果()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年01期
页码:
140-141
栏目:
药物与临床
出版日期:
2020-01-01

文章信息/Info

Title:
Effect of Ozagrel Combined with Edaravone on Acute Cerebral Infarction
文章编号:
1006-1959（2020）01-0140-02
作者:
曹金强; 毛士明; 汪万国
（湖北省枝江市人民医院神经内科，湖北 枝江 443200）
Author(s):
CAO Jin-qiang; MAO Shi-ming; WANG Wan-guo
(Department of Neurology,Zhijiang People’s Hospital,Zhijiang 443200,Hubei,China)
关键词:
奥扎格雷; 依达拉奉; 急性脑梗死
Keywords:
Ozagrel; Edaravone; Acute cerebral infarction
分类号:
R743.33
DOI:
10.3969/j.issn.1006-1959.2020.01.044
文献标志码:
A
摘要:
目的 观察奥扎格雷联合依达拉奉治疗急性脑梗死的效果。方法 选择2018年5月~2019年5月在我院诊治的急性脑梗死患者106例，采用随机数字表法分为对照组和观察组，各53例。对照组采用奥扎格雷治疗，观察组在对照组基础上联合依达拉奉治疗，比较两组临床治疗总有效率、治疗前后神经功能缺损评分（NIHSS）和日常生活能力评分（Barthel）、临床不良反应。结果 观察组治疗总有效率为94.33%，高于对照组的81.13%，差异有统计学意义（P＜0.05）；治疗后两组NIHSS评分均低于治疗前，且观察组低于对照组，差异有统计学意义（P＜0.05）；治疗后两组Barthel评分均高于治疗前，且观察组高于对照组，差异有统计学意义（P＜0.05）；观察组临床不良反应率为5.66%，与对照组的7.54%比较，差异无统计学意义（P＞0.05）。结论 奥扎格雷联合依达拉奉治疗急性脑梗死效果确切，有助于改善神经功能，提高患者日常生活能力，同时临床不良反应小，联合用药方案安全可行，值得临床应用。
Abstract:
Objective To observe the effect of ozagrel combined with edaravone on acute cerebral infarction. Methods A total of 106 patients with acute cerebral infarction diagnosed and treated in our hospital from May 2018 to May 2019 were selected and randomly divided into a control group and an observation group, with 53 cases in each group. The control group was treated with ozagrel, and the observation group was combined with edaravone treatment on the basis of the control group. The total effective rate of clinical treatment, neurological deficit score (NIHSS), daily life ability score (Barthel), and clinical adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 94.33%, which was higher than 81.13% in the control group,the difference was statistically significant (P<0.05). After treatment, the NIHSS scores of the two groups were lower than before the treatment, and the observation group was lower than the control group,the difference wasstatistically significant (P<0.05); the Barthel scores of the two groups after treatment were higher than before the treatment, and the observation group was higher than the control group, the difference was statistically significant (P<0.05); the clinical adverse reaction rate of the observation group was 5.66% compared with 7.54% of the control group, the difference was not statistically significant (P>0.05).Conclusion Ozagrel combined with edaravone is effective in the treatment of acute cerebral infarction, which is helpful to improve neurological function and improve the daily living ability of patients. At the same time, the clinical adverse reactions are small, and the combined drug regimen is safe and feasible, which is worthy of clinical application.

参考文献/References:

[1]高爽,郭树彬．脓毒症急性肾损伤的评价方法及临床意义[J].中国急救医学,2014(9):769-774. [2]陈燕,孟艳.人参二醇组皂苷改善内毒素诱导急性肾损伤小鼠肾功能的机制[J].中国老年学杂志,2014,34(10):2806-2809 [3]朱丹丹,于健,王之余.盲肠结扎穿孔术大鼠外周血内皮细胞微粒改变及意义[J].中华实验外科杂志,2016,33(3):614-617 [4]朴英花,朴兰.右美托咪定药理学特点及临床应用新进展[J].中国实用医药,2015,7(35):243-244. [5]周少丽,谭芳,陈裕洁.右美托咪啶用于治疗脓毒症的研究及其进展[J].实用医学杂志,2016,29(15):2421-2422.

相似文献/References:

[1]刘 阳,李新萍,吴细建.依达拉奉联合脑苷肌肽治疗重症颅脑损伤患者的疗效[J].医学信息,2019,32(22):103.[doi:10.3969/j.issn.1006-1959.2019.22.032]
　LIU Yang,LI Xin-ping,WU Xi-jian.Edaravone Combined with Cerebroside Carnosine in the Treatment of Patients with Severe Head Injury[J].Medical Information,2019,32(01):103.[doi:10.3969/j.issn.1006-1959.2019.22.032]
[2]谢海辉,张 曙,黎建文,等.依达拉奉对老年髋关节置换术患者血清CXCL13水平及PND的影响[J].医学信息,2020,33(05):67.[doi:10.3969/j.issn.1006-1959.2020.05.020]
　XIE Hai-hui,ZHANG Shu,LI Jian-wen,et al.Effect of Edaravone on Serum CXCL13 Level and PND in Elderly Patients with Hip Replacement[J].Medical Information,2020,33(01):67.[doi:10.3969/j.issn.1006-1959.2020.05.020]
[3]黄绮娟,陈劲新,黄小良.丁苯酞联合依达拉奉治疗非致残性脑梗死的效果及对患者神经功能的影响[J].医学信息,2021,34(08):144.[doi:10.3969/j.issn.1006-1959.2021.08.038]
　HUANG Qi-juan,CHEN Jin-xin,HUANG Xiao-liang.The Effect of Butylphthalide Combined with Edaravone in the Treatment of Non-disabling Cerebral Infarction and Its Influence on Patients’ Neurological Function[J].Medical Information,2021,34(01):144.[doi:10.3969/j.issn.1006-1959.2021.08.038]
[4]管海兵,葛 胜,沈 斌.阿托伐他汀钙联合依达拉奉对急性脑梗死患者hs-CRP和同型半胱氨酸水平的影响[J].医学信息,2021,34(19):110.[doi:10.3969/j.issn.1006-1959.2021.19.028]
　GUAN Hai-bing,GE Sheng,SHEN Bin.The Effect of Atorvastatin Calcium Combined with Edaravone on hs-CRP andHomocysteine Levels in Patients with Acute Cerebral Infarction[J].Medical Information,2021,34(01):110.[doi:10.3969/j.issn.1006-1959.2021.19.028]
[5]荣丽红,张恒春.血栓通联合依达拉奉治疗急性脑梗塞患者的效果[J].医学信息,2021,34(22):148.[doi:10.3969/j.issn.1006-1959.2021.22.046]
　RONG Li-hong,ZHANG Heng-chun.Effect of Xueshuantong Combined with Edaravone on Patients with Acute Cerebral Infarction[J].Medical Information,2021,34(01):148.[doi:10.3969/j.issn.1006-1959.2021.22.046]
[6]张 皓.阿司匹林联合奥扎格雷双抗血小板治疗脑梗死的疗效及对患者血清hs-CRP及D-D水平的影响[J].医学信息,2023,36(13):123.[doi:10.3969/j.issn.1006-1959.2023.13.025]
　ZHANG Hao.Effect of Aspirin Combined with Ozagrel Dual Antiplatelet Therapy on Cerebral Infarction and its Effect on Serum hs-CRP and D-D Levels in Patients with Cerebral Infarction[J].Medical Information,2023,36(01):123.[doi:10.3969/j.issn.1006-1959.2023.13.025]

更新日期/Last Update: 2020-01-01